| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nilufar Mossaheb, Rainer M Kaufman. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatric disease and treatment. vol 8. 2012-08-23. PMID:22701324. |
role of aripiprazole in treatment-resistant schizophrenia. |
2012-08-23 |
2023-08-12 |
Not clear |
| Nilufar Mossaheb, Rainer M Kaufman. Role of aripiprazole in treatment-resistant schizophrenia. Neuropsychiatric disease and treatment. vol 8. 2012-08-23. PMID:22701324. |
the aim of this review was to evaluate the evidence for aripiprazole as a potential strategy in monotherapy or combination therapy for patients with treatment-resistant schizophrenia. |
2012-08-23 |
2023-08-12 |
Not clear |
| Sandra Schönfelder, Frederike Schirmbeck, Robert Waltereit, Susanne Englisch, Mathias Zin. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clinical neuropharmacology. vol 34. issue 6. 2012-08-20. PMID:22104635. |
aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. |
2012-08-20 |
2023-08-12 |
Not clear |
| Min-Hyeon Park, Changsu Han, Chi-Un Pae, Soo-Jung Lee, Ashwin A Patkar, Praksh S Masand, Wolfgang W Fleischhacke. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert review of neurotherapeutics. vol 11. issue 11. 2012-07-30. PMID:22014131. |
aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. |
2012-07-30 |
2023-08-12 |
Not clear |
| Min-Hyeon Park, Changsu Han, Chi-Un Pae, Soo-Jung Lee, Ashwin A Patkar, Praksh S Masand, Wolfgang W Fleischhacke. Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment. Expert review of neurotherapeutics. vol 11. issue 11. 2012-07-30. PMID:22014131. |
hence this article aims to summarize the currently available clinical trial data of aripiprazole published from a number of large-scale randomized controlled studies, including a newer formulation of intramuscular injection as well as a once-monthly intramuscular depot formulation, to update knowledge of treatment options in patients with schizophrenia. |
2012-07-30 |
2023-08-12 |
Not clear |
| Rosario de Arce Cordón, Evelin Eding, Joao Marques-Teixeira, Vihra Milanova, Elmars Rancans, Andreas Schreine. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). European archives of psychiatry and clinical neuroscience. vol 262. issue 2. 2012-07-16. PMID:21809168. |
clinically stable adults with schizophrenia or schizoaffective disorder previously treated with oral risperidone, olanzapine, or an oral conventional antipsychotic were randomized to rlai or aripiprazole. |
2012-07-16 |
2023-08-12 |
Not clear |
| Kenji Nemoto, Kazuo Mihara, Akifumi Nakamura, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kond. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 34. issue 2. 2012-07-11. PMID:22377745. |
effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in japanese patients with schizophrenia. |
2012-07-11 |
2023-08-12 |
Not clear |
| Kenji Nemoto, Kazuo Mihara, Akifumi Nakamura, Goyo Nagai, Shoko Kagawa, Takeshi Suzuki, Tsuyoshi Kond. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 34. issue 2. 2012-07-11. PMID:22377745. |
the effects of paroxetine coadministration on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, were studied in 14 japanese patients with schizophrenia. |
2012-07-11 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Asuka Katsuki, Kenji Hayashi, Kiyokazu Atake, Masaru Tomita, Jun Nakamur. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Human psychopharmacology. vol 27. issue 1. 2012-06-29. PMID:22213405. |
aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated japanese schizophrenia patients. |
2012-06-29 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Asuka Katsuki, Kenji Hayashi, Kiyokazu Atake, Masaru Tomita, Jun Nakamur. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. Human psychopharmacology. vol 27. issue 1. 2012-06-29. PMID:22213405. |
we investigated the effects of aripiprazole on plasma levels of brain-derived neurotrophic factor (bdnf) and catecholamine metabolites in first-episode untreated schizophrenia patients. |
2012-06-29 |
2023-08-12 |
Not clear |
| Kathryn Brotzge, Manoochehr Manshadi, Rif S El-Mallak. Intermittent aripiprazole for schizophrenia. Schizophrenia research. vol 134. issue 2-3. 2012-06-04. PMID:22209538. |
intermittent aripiprazole for schizophrenia. |
2012-06-04 |
2023-08-12 |
Not clear |
| Akshay Gopinathan Nair, Aditya Gopinathan Nair, Ronnie Jacob George, Jyotirmay Biswas, Rashmin Anilkumar Gandh. Aripiprazole induced transient myopia: a case report and review of literature. Cutaneous and ocular toxicology. vol 31. issue 1. 2012-05-29. PMID:21830909. |
we report a case of transient myopia in a 33-year-old male who was being treated for schizophrenia with oral quetiapine and was recently supplemented with aripiprazole. |
2012-05-29 |
2023-08-12 |
Not clear |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Azuma Mori, Keiko Kanno, Qiaohui Yang, Hirobumi Mashiko, Yoshihiko Numata, Shin-Ichi Niw. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198450. |
effects of aripiprazole and the taq1a polymorphism in the dopamine d2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. |
2012-05-23 |
2023-08-12 |
Not clear |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Azuma Mori, Keiko Kanno, Qiaohui Yang, Hirobumi Mashiko, Yoshihiko Numata, Shin-Ichi Niw. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198450. |
we examined the effects of the taq1a polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a drd2 partial agonist. |
2012-05-23 |
2023-08-12 |
Not clear |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Azuma Mori, Keiko Kanno, Qiaohui Yang, Hirobumi Mashiko, Yoshihiko Numata, Shin-Ichi Niw. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198450. |
thirty japanese patients with schizophrenia were treated with aripiprazole for 6 weeks. |
2012-05-23 |
2023-08-12 |
Not clear |
| Itaru Miura, Satoshi Takeuchi, Akihiko Katsumi, Azuma Mori, Keiko Kanno, Qiaohui Yang, Hirobumi Mashiko, Yoshihiko Numata, Shin-Ichi Niw. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. Journal of clinical psychopharmacology. vol 32. issue 1. 2012-05-23. PMID:22198450. |
aripiprazole improved the acute symptoms of schizophrenia and decreased phva in responders (p = 0.023) but not in nonresponders (p = 0.28). |
2012-05-23 |
2023-08-12 |
Not clear |
| Yuatro Suzuki, Takuro Sugai, Shin Ono, Kazushi Sawamura, Naoki Fukui, Junzo Watanabe, Nobuto Tsuneyama, Toshiyuki Somey. Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia. Journal of clinical psychopharmacology. vol 31. issue 4. 2012-05-15. PMID:21720226. |
changes in the metabolic parameters and qtc interval after switching from olanzapine to aripiprazole in japanese patients with stable schizophrenia. |
2012-05-15 |
2023-08-12 |
Not clear |
| Salvatore Gentil. Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders. Paediatric drugs. vol 13. issue 5. 2012-03-28. PMID:21888443. |
nevertheless, the results of this review allow us to suggest the effectiveness of three sgas (aripiprazole, olanzapine, and risperidone) in the short-term treatment of both early-onset schizophrenia and bipolar mania, although such agents show different safety profiles. |
2012-03-28 |
2023-08-12 |
Not clear |
| Sung Woo Park, Vu Thi Phuong, Chan Hong Lee, Jung Goo Lee, Mi Kyoung Seo, Hye Yeon Cho, Zheng Huan Fang, Bong Ju Lee, Young Hoon Ki. Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress. Neuroscience research. vol 71. issue 4. 2012-03-05. PMID:21893111. |
these results suggest that olanzapine and aripiprazole may exert beneficial effects by upregulating bdnf, phosphorylated gsk-3β, and β-catenin in patients with schizophrenia. |
2012-03-05 |
2023-08-12 |
rat |
| Takashi Ueda, Shinya Ugawa, Yusuke Ishida, Shoichi Shimad. Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. European journal of pharmacology. vol 671. issue 1-3. 2012-03-01. PMID:21951966. |
aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders. |
2012-03-01 |
2023-08-12 |
Not clear |